CORE--CLINICAL AND MOLECULAR EPIDEMIOLOGY

这一核心将提供全面的临床和分子流行病学 对本计划项目的相关组件提供支持。这个核心将 确定并登记所有符合条件的UTMDACC患者，这些患者的活组织检查未证实 黑色素瘤皮肤癌形成的患者池中将有哪些病例 根据特定的资格标准为每个项目选择。 详细的临床和流行病学数据以及血液样本将 为所有病人收集的。一种新的分子成分将研究p53和 所有可用的肿瘤标本中都存在RAS突变。此外，对于项目 3(魏博士，皮肤癌的DNA修复和染色体不稳定)300 将确定非癌症对照；对于项目5(利普曼博士， 侵袭性皮肤癌的生物学治疗方法)数据将是 收集的是生活质量的组成部分。这个核心也将是 负责数据质量、管理和检索。数据将是 在最新、用户友好且易于访问的数据库中进行维护 促进来自所有项目和核心的数据的整合。

This core will provide comprehensive clinical and molecular epidemiologic support to the relevant components of this Program Project. This core will ascertain and enroll all eligible UTMDACC patients with biopsy-proven non- melanoma skin cancer to form a pool of patients from which cases will be selected for each project according to the specific eligibility criteria. Detailed clinical and epidemiologic data and a blood sample will be collected for all patients. A new molecular component will study p53 and ras mutations in all available tumor specimens. In addition, for Project 3 (Dr. Wei, DNA repair and chromosomal instability in skin cancers) 300 non-cancer controls will be identified; and for Project 5 (Dr. Lippman, Biologic approach to therapy of aggressive skin cancer) data will be collected for the Quality of life component. This core will also be responsible for data quality, management, and retrieval. Data will be maintained in an up-to-date, user friendly, and easily accessible database to facilitate the integration of data from all projects and cores.